Morgan Stanley released a weekly prescription tracking update for selected U.S. neurology products based on IQVIA data for the week ending May 29.
Antipsychotic market overview
The U.S. antipsychotic market recorded a 2.9% rise in total prescriptions year-over-year for the reported week, which included the Memorial Day holiday. Longer-run measures were also positive: the rolling 4-week total prescription count rose 2.6% year-over-year, and the rolling 12-week total increased 2.2% year-over-year.
However, on a week-over-week basis the category showed a pullback: total prescriptions declined 8.8% compared with the prior week, which had seen a 2.5% increase.
Bipolar depression medications
Total prescriptions for bipolar depression drugs fell 8.1% week-over-week. The rolling 4-week total prescription count decreased 1.7% on a week-over-week basis. Year-over-year growth for this segment stood at 3.8% for the current week, 3.4% for the rolling 4-week period, and 2.8% for the rolling 12-week period.
Selected branded products
- Nuplazid (Acadia): Weekly total prescriptions for Nuplazid, indicated for Parkinson’s disease psychosis, declined 2% week-over-week and rose 2% year-over-year. The rolling 12-week count for Nuplazid fell 1% year-over-year. New prescriptions made up 46% of total prescriptions during the week.
- Auvelity (Axsome): Auvelity, for major depressive disorder, posted an 8% week-over-week decline in total weekly prescriptions but a 34% increase year-over-year. The rolling 12-week total for Auvelity was up 32% year-over-year. New prescriptions represented 57% of the week’s total for the product.
- Ingrezza (Neurocrine): Ingrezza, used for tardive dyskinesia and Huntington’s disease chorea, saw a 14% drop in weekly total prescriptions versus the prior week and a 19% increase year-over-year. Its rolling 12-week count rose 23% year-over-year. New prescriptions comprised 44% of the week’s total for Ingrezza.
The weekly snapshot highlights contrasts between short-term weekly volatility and steadier year-over-year and multiweek rolling trends across the antipsychotic and related neurology categories.